



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 50757/S-020

**SUPPLEMENT APPROVAL**

Takeda Pharmaceuticals USA, Inc.  
Attention: Valerie Tews, RAC  
Manager, Regulatory Affairs Strategy  
One Takeda Parkway  
Deerfield, IL 60015

Dear Ms. Tews:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 14, 2016, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREVPAC (lansoprazole/amoxicillin/clarithromycin).

We also refer to our letter dated June 15, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for class of drugs containing a proton pump inhibitor (PPI) component. This information pertains to the risk of cutaneous and systemic lupus erythematosus.

This supplemental new drug application provides for revisions to the labeling for PREVPAC (lansoprazole/amoxicillin/clarithromycin), consistent with our June 15, 2016 letter and September 26, 2016 correspondence. These revisions include the additions of the risks of cutaneous and systemic lupus erythematosus to the Warnings and Information for Patients sections of labeling.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, Safety Regulatory Project Manager, at (301) 796-0803.

Sincerely,

*{See appended electronic signature page}*

Joseph G. Toerner, M.D., M.P.H.  
Deputy Director for Safety  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOSEPH G TOERNER  
10/24/2016